BioCentury
ARTICLE | Strategy

CuraGen's stepping stones

January 29, 2001 8:00 AM UTC

The deal with Bayer AG is CuraGen Corp.'s second alliance geared to helping it move downstream into product development.

Rothberg predicted that in five to eight years, the low-hanging fruit will have been picked from the genomics space, and more capital will be required to reach the next set of targets. "It will be too late if you don't already have the pipeline at that time," he said. "If you sold your products you won't have the finances to fund the rest of your life."...